Cagrilintide (revision 1)
Old revision·09:00, 13 Aug 2024·IcodecIndra
This is an old revision of this page, as it stood at 09:00, 13 Aug 2024, saved by IcodecIndra with the summary new article: compound, expansion welcome. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Cagrilintide | |
|---|---|
| Class | Amylin receptor agonist |
| Route | Subcutaneous, weekly |
| Status | Investigational; not approved alone |
| Combination | CagriSema with semaglutide |
| Compound infobox · conventions | |
Cagrilintide is a long-acting analogue of amylin, engineered to resist the aggregation that makes the native human sequence undevelopable and acylated for albumin binding so that weekly dosing is possible.[1]
Its actions follow those of amylin: slowed gastric emptying, suppression of postprandial glucagon, and reduced food intake through hindbrain circuits distinct from the GLP-1 pathway.[2]
References
- ^ Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." The Lancet 398(10317):2160–2172 (2021). PMID 34798060.
- ^ Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. "Amylin: pharmacology, physiology, and clinical potential." Pharmacological Reviews 67(3):564–600 (2015). PMID 26071095.
Categories: